The TNFR2 mAb significantly improved the efficacy of PTX, inhibiting the growth of primary tumors and prolonging the survival of tumor-bearing mice (Fig. 8B, C) compared to controls. This evidence concerns the gene TNFRSF1B and neoplasm.